Here’s why the Mesoblast (ASX:MSB) share price is plunging
Jaz Harrison
December 18, 2020
The Mesoblast Limited (ASX:MSB) share price has plunged 43% after
Mesoblast Ltd (ASX:MSB) is a leader in providing allogeneic (off the shelf) cellular medicines. It owns a portfolio of late-stage product candidates with three product candidates in Phase 3 trials, being acute graft versus host disease, chronic heart failure and chronic low back pain due to degenerative disc disease. The company has facilities in Melbourne, New York, Singapore and Texas and is listed on the ASX and the NASDAQ.
The Mesoblast Limited (ASX:MSB) share price has plunged 43% after
The Mesoblast Limited (ASX:MSB) share price has sunk around 10%
The Mesoblast Limited (ASX: MSB) share price could soar today
The share price of biotechnology company Imugene Limited (ASX: IMU)
The S&P/ASX 200 (INDEXASX:XJO) is tipped to open higher on
The Mesoblast Limited (ASX:MSB) share price is going nuts this
The Mesoblast Limited (ASX:MSB) share price is surging this morning
It has been an absolute rollercoaster ride for anyone who
Novonix Ltd (ASX:NVX) was the most-traded stock on the ASX
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
